A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab.

ABSTRACT:

Purpose

We investigated whether microRNA expression data from glioblastoma could be used to produce a profile that defines a bevacizumab responsive group of patients.

Patients and methods

TCGA microRNA expression data from tumors resected at first diagnosis of glioblastoma in patients treated with bevacizumab at any time during the course of their disease were randomly separated into training (n = 50) and test (n = 37) groups for model generation. MicroRNA-seq data for 51 patients whose treatment included bevacizumab in the BELOB trial were used as an independent validation cohort.

Results

Using penalized regression we identified 8 microRNAs as potential predictors of overall survival in the training set. We dichotomized the response score based on the most prognostic

SUBMITTER: Hayes J 

PROVIDER: S-EPMC5423205 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature